Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.
Sanofi American Depositary Shares (NASDAQ: SNY) represent an R&D driven, AI-powered biopharma company that regularly issues news on its medicines, vaccines, pipeline programs, and strategic initiatives. Company communications describe a focus on immunology, autoimmune diseases, rare diseases, diabetes, respiratory conditions, and infectious disease prevention, which generates a steady flow of clinically and commercially relevant updates.
News about Sanofi often covers clinical trial milestones, regulatory decisions, and collaborations. Recent examples include collaborations with Dren Bio on next-generation B-cell depletion therapies for autoimmune disease, a collaboration and license agreement with EVOQ Therapeutics around NanoDisc technology for autoimmune conditions, and a partnership with Revvity to support development and validation of a type 1 diabetes autoantibody assay for early detection. Sanofi also reports on RSV prevention with BEYFORTUS, COPD care initiatives with Viz.ai and Regeneron, and progress in alpha-1 antitrypsin deficiency emphysema.
Investors and healthcare observers will also find corporate and strategic news, such as Sanofi’s intention to invest at least $20 billion in the United States through 2030, the opening of new flagship offices in Morristown, New Jersey, and the planned acquisition of Blueprint Medicines to expand its rare immunological disease portfolio. Additional releases highlight community-focused programs like the Healthy Futures Solution Fund and the expansion of the Insulins Valyou Savings Program in the US.
This SNY news page aggregates these announcements, providing a single place to follow Sanofi’s clinical data readouts, regulatory updates, partnerships, acquisitions, access and affordability initiatives, and other developments that shape the company’s role in global healthcare.
Viz.ai has announced a multi-year partnership with Sanofi (SNY) and Regeneron (REGN) to develop and evaluate an AI-powered workflow solution for Chronic Obstructive Pulmonary Disease (COPD). The collaboration will focus on deploying the Viz COPD module, which uses electronic health record (EHR) data and artificial intelligence to improve detection and management of high-risk COPD patients.
The solution will be implemented across Viz.ai's network of over 1,700 hospitals and health systems, reaching more than 60,000 healthcare providers. COPD, affecting an estimated 392 million people globally and ranking as the fourth leading cause of death worldwide, remains underprioritized and undertreated. The AI-powered system will screen and triage patients using natural language processing, aligning with established clinical guidelines to identify high-risk individuals requiring follow-up care.
Sanofi (SNY) has announced that Chrissy Teigen has joined as the new celebrity spokesperson for their Screen For Type 1 movement. The partnership, revealed on T1D Day, aims to promote early type 1 diabetes risk detection through screening.
Teigen's involvement stems from her personal experience with her son Miles, who was diagnosed with type 1 diabetes at age six in 2024 after an unexpected medical emergency. This reflects a common scenario, as approximately 64,000 Americans are diagnosed annually with type 1 diabetes, with up to 40% unaware of their condition until experiencing life-threatening complications.
The Screen For Type 1 initiative emphasizes that the disease can be detected through a single blood test that identifies diabetes-related autoantibodies before symptoms appear. While type 1 diabetes cannot be prevented, early detection can help families better prepare and plan for managing the condition.
Sanofi (SNY) has announced the immediate adoption of FDA-selected influenza strains for manufacturing its vaccine portfolio for the 2025-26 flu season in the US. The selected strains match those already in production by the company. Sanofi plans to begin shipping vaccines this summer to healthcare facilities for early season administration.
The announcement comes amid one of the worst flu seasons in decades, with CDC estimates showing 40 million illnesses, 520,000 hospitalizations, and 22,000 deaths through March 1. The company's 2025-26 US portfolio will include FLUZONE® High-Dose, FLUBLOK®, and FLUZONE® vaccines, covering patients from 6 months through 65+ years of age.
Sanofi and Orano Med have entered into an agreement to develop next-generation radioligand medicines for rare cancers. They will invest in a new entity under the Orano Med brand, focusing on discovery, design, and clinical development of radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes. This follows Sanofi's exclusive licensing agreement with Orano Med and RadioMedix for AlphaMedix™.
The collaboration aims to combine Sanofi's biopharma expertise with Orano's nuclear technology to advance cancer treatments. Sanofi will make an equity investment of €300 million, acquiring approximately 16% stake in the new entity valued at €1.9bn. The partnership is expected to accelerate the development of Orano Med's pipeline and leverage its capabilities in lead-212 based therapies.
Both companies are members of the Paris Saclay Cancer Cluster and aim to contribute to the France 2030 plan for oncology innovation. The agreement is subject to standard regulatory approvals.
Sanofi announced that the FDA has updated the label for FLUBLOK (Influenza Vaccine) to include data from a new safety study involving pregnant individuals 18 years and older. The study, involving over 48,000 pregnant individuals across multiple flu seasons, demonstrated that FLUBLOK safety is consistent with a standard-dose flu vaccine and pregnancy-related outcomes in the general population.
Key findings include:
- No increased risk of pregnancy, birth or neonatal/infant outcomes compared to standard-dose flu vaccine
- Similar rates of pregnancy outcomes between FLUBLOK and standard-dose vaccine groups
- Comparable birth and neonatal/infant outcomes between the two groups
The CDC, ACIP, and ACOG recommend flu vaccination for pregnant individuals due to their higher risk for severe illness and complications from flu.
Sanofi is shipping BEYFORTUS (nirsevimab-alip) in the US to protect babies against RSV disease. The company aims to provide access for every eligible baby, with a new FDA-approved manufacturing line expanding capacity to meet demand. BEYFORTUS is the first long-acting monoclonal antibody approved for RSV prevention in newborns and infants up to 24 months old.
Sanofi has collaborated with the White House, CDC, and FDA to ensure wide availability. The company has launched a Reservation Program for private healthcare providers and is working with AstraZeneca to build inventory for current and future seasons. Another filling line is expected to provide doses for the 2024/2025 season, further increasing production capacity.
Sanofi has entered an exclusive licensing agreement with RadioMedix and Orano Med for AlphaMedixTM, a late-stage targeted alpha therapy (TAT) project for treating neuroendocrine tumors (NETs). AlphaMedixTM has received Breakthrough Therapy Designation from the FDA for gastroenteropancreatic NETs. Phase 1 and 2 clinical studies showed a 62.5% durable response rate. Under the agreement, Sanofi will handle global commercialization, while Orano Med will manage manufacturing. RadioMedix and Orano Med will receive a €100 million upfront payment and up to €220 million in sales milestones, plus tiered royalties. This collaboration aligns with Sanofi's focus on oncology innovation and rare cancers.
Sanofi has begun shipping influenza vaccines across the U.S. for the 2024/25 flu season, starting on July 10, with shipments continuing through October. These vaccines, including Fluzone High-Dose, Flublok, and Fluzone, are designed to protect against three strains of influenza identified as the most likely to cause illness this season. Sanofi emphasizes the importance of flu vaccination to reduce risks such as pneumonia and cardiac events, especially in vulnerable populations. The company, a leader in global vaccine distribution, aims to support fall immunization campaigns by supplying healthcare providers, pharmacies, and other immunizers.